S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NYSE:ABC

AmerisourceBergen (ABC) Stock Forecast, Price & News

$150.18
+0.80 (+0.54%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$148.08
$151.68
50-Day Range
$148.97
$165.73
52-Week Range
$111.34
$167.19
Volume
2.26 million shs
Average Volume
1.92 million shs
Market Capitalization
$31.46 billion
P/E Ratio
18.31
Dividend Yield
1.23%
Beta
0.45
30 days | 90 days | 365 days | Advanced Chart
Receive ABC News and Ratings via Email

Sign-up to receive the latest news and ratings for AmerisourceBergen and its competitors with MarketBeat's FREE daily newsletter.

AmerisourceBergen logo

About AmerisourceBergen

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drugs, proprietaries, & sundries
Sub-Industry
Health Care Distributors
Sector
Medical
CUSIP
03073E10
Employees
42,000
Year Founded
2001

Sales & Book Value

Annual Sales
$213.99 billion
Cash Flow
$11.82 per share
Book Value
$4.33 per share

Profitability

Net Income
$1.54 billion
Pretax Margin
1.07%

Debt

Price-To-Earnings

Miscellaneous

Free Float
149,976,000
Market Cap
$31.46 billion
Optionable
Optionable

Company Calendar

Ex-Dividend for 2/28 Dividend
2/11/2022
Dividend Payable
2/28/2022
Last Earnings
5/04/2022
Ex-Dividend for 5/31 Dividend
5/13/2022
Today
5/22/2022
Dividend Payable
5/31/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
9/30/2022

Social Links


MarketRank

Overall MarketRank

2.90 out of 5 stars

Medical Sector

21st out of 1,416 stocks

Drugs, Proprietaries, & Sundries Industry

3rd out of 8 stocks

Analyst Opinion: 1.1Community Rank: 4.4Dividend Strength: 4.2Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -













AmerisourceBergen (NYSE:ABC) Frequently Asked Questions

Is AmerisourceBergen a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AmerisourceBergen in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AmerisourceBergen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABC, but not buy additional shares or sell existing shares.
View analyst ratings for AmerisourceBergen
or view top-rated stocks.

When is AmerisourceBergen's next earnings date?

AmerisourceBergen is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for AmerisourceBergen
.

How were AmerisourceBergen's earnings last quarter?

AmerisourceBergen Co. (NYSE:ABC) announced its earnings results on Wednesday, May, 4th. The company reported $3.22 earnings per share for the quarter, topping the consensus estimate of $2.99 by $0.23. The company had revenue of $57.72 billion for the quarter, compared to analyst estimates of $57.26 billion. AmerisourceBergen had a trailing twelve-month return on equity of 349.46% and a net margin of 0.75%. AmerisourceBergen's quarterly revenue was up 17.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.53 earnings per share.
View AmerisourceBergen's earnings history
.

How often does AmerisourceBergen pay dividends? What is the dividend yield for AmerisourceBergen?

AmerisourceBergen declared a quarterly dividend on Wednesday, May 4th. Shareholders of record on Monday, May 16th will be paid a dividend of $0.46 per share on Tuesday, May 31st. This represents a $1.84 dividend on an annualized basis and a dividend yield of 1.23%. The ex-dividend date of this dividend is Friday, May 13th.
View AmerisourceBergen's dividend history
.

Is AmerisourceBergen a good dividend stock?

AmerisourceBergen pays an annual dividend of $1.84 per share and currently has a dividend yield of 1.23%. AmerisourceBergen has been increasing its dividend for 18 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of AmerisourceBergen is 22.44%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AmerisourceBergen will have a dividend payout ratio of 15.86% next year. This indicates that AmerisourceBergen will be able to sustain or increase its dividend.
View AmerisourceBergen's dividend history.

What guidance has AmerisourceBergen issued on next quarter's earnings?

AmerisourceBergen issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $10.80-$11.05 for the period, compared to the consensus EPS estimate of $10.79. The company issued revenue guidance of -.

What price target have analysts set for ABC?

7 equities research analysts have issued twelve-month price objectives for AmerisourceBergen's shares. Their forecasts range from $145.00 to $187.00. On average, they anticipate AmerisourceBergen's stock price to reach $164.57 in the next twelve months. This suggests a possible upside of 9.6% from the stock's current price.
View analysts' price targets for AmerisourceBergen
or view top-rated stocks among Wall Street analysts.

Who are AmerisourceBergen's key executives?
AmerisourceBergen's management team includes the following people:
What is Steve Collis' approval rating as AmerisourceBergen's CEO?

447 employees have rated AmerisourceBergen CEO Steve Collis on Glassdoor.com. Steve Collis has an approval rating of 83% among AmerisourceBergen's employees.

Who are some of AmerisourceBergen's key competitors?
What other stocks do shareholders of AmerisourceBergen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AmerisourceBergen investors own include NVIDIA (NVDA), Intel (INTC), AbbVie (ABBV), Walt Disney (DIS), CVS Health (CVS), Johnson & Johnson (JNJ), AT&T (T), JPMorgan Chase & Co. (JPM), Home Depot (HD) and Pfizer (PFE).

What is AmerisourceBergen's stock symbol?

AmerisourceBergen trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABC."

Who are AmerisourceBergen's major shareholders?

AmerisourceBergen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.80%), BlackRock Inc. (7.87%), JPMorgan Chase & Co. (3.54%), State Street Corp (3.31%), Boston Partners (2.23%) and Capital Research Global Investors (1.63%). Company insiders that own AmerisourceBergen stock include Elizabeth S Campbell, Gina Clark, Henry Wadsworth Mcgee III, Jane E Md Henney, John G Chou, John G Chou, Lazarus Krikorian, Robert P Mauch, Silvana Battaglia, Steven H Collis and Walgreens Boots Alliance, Inc.
View institutional ownership trends for AmerisourceBergen
.

Which institutional investors are selling AmerisourceBergen stock?

ABC stock was sold by a variety of institutional investors in the last quarter, including Suvretta Capital Management LLC, Beutel Goodman & Co Ltd., JPMorgan Chase & Co., First Trust Advisors LP, Glenview Capital Management LLC, TimesSquare Capital Management LLC, TD Asset Management Inc., and ANTIPODES PARTNERS Ltd. Company insiders that have sold AmerisourceBergen company stock in the last year include Elizabeth S Campbell, Gina Clark, John G Chou, Lazarus Krikorian, Robert P Mauch, Silvana Battaglia, Steven H Collis, and Walgreens Boots Alliance, Inc.
View insider buying and selling activity for AmerisourceBergen
or view top insider-selling stocks.

Which institutional investors are buying AmerisourceBergen stock?

ABC stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Invesco Ltd., Envestnet Asset Management Inc., The Manufacturers Life Insurance Company , Strs Ohio, DekaBank Deutsche Girozentrale, and Goldman Sachs Group Inc..
View insider buying and selling activity for AmerisourceBergen
or or view top insider-buying stocks.

How do I buy shares of AmerisourceBergen?

Shares of ABC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AmerisourceBergen's stock price today?

One share of ABC stock can currently be purchased for approximately $150.18.

How much money does AmerisourceBergen make?

AmerisourceBergen has a market capitalization of $31.46 billion and generates $213.99 billion in revenue each year. The company earns $1.54 billion in net income (profit) each year or $8.199990 on an earnings per share basis.

How many employees does AmerisourceBergen have?

AmerisourceBergen employs 42,000 workers across the globe.

Does AmerisourceBergen have any subsidiaries?

The following companies are subsidiares of AmerisourceBergen: AB Singapore Investments Pte Ltd, AB UK Holdings Ltd, ASD Specialty Healthcare LLC, Access M.D., Alliance Healthcare, Amerisource Receivables Financial Corporation, AmerisourceBergen Drug Corporation, AmerisourceBergen Global Holdings GmbH, AmerisourceBergen Global Manufacturer Services GmbH, AmerisourceBergen Group GmbH, AmerisourceBergen International Holdings Inc., AmerisourceBergen Luxembourg S.a.r.L., AmerisourceBergen Services Corporation, AmerisourceBergen Sourcing LLC, AmerisourceBergen Specialty Group LLC, Anderson Packaging, AutoMed Technologies, BPL Group LLC, BPLH Ireland Unlimited Company, Bellco Health, Brecon Pharmaceuticals, Bridge Medical Inc, CD Smith Healthcare, H. D. Smith, IgG America, International Physician Networks L.L.C., IntrinsiQ, Lash Group, MWI Veterinary Supply, Network for Medical Communications & Research, PharMEDium Healthcare, Pharmacy Healthcare Solutions, Premier Source, St. Francis Group, Trent Drug, US Bioservices, Wight Nederland Holdco 2 BV, World Courier, World Courier Group S.à r.l., and Xcenda.

When was AmerisourceBergen founded?

AmerisourceBergen was founded in 2001.

What is AmerisourceBergen's official website?

The official website for AmerisourceBergen is www.amerisourcebergen.com.

How can I contact AmerisourceBergen?

AmerisourceBergen's mailing address is 1300 MORRIS DRIVE, CHESTERBROOK PA, 19087. The company can be reached via phone at (610) 727-7000, via email at [email protected], or via fax at 800-640-5221.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.